Institute of Human Virology at International HBV Meeting

The International HBV(hepatitis B) 2025 meeting took place in Berlin, Germany, in September. This annual conference promotes information exchange between scientists and individuals living with hepatitis B and D, fostering collaboration among researchers, public health professionals, and affected communities. The goal: to accelerate pathways toward an HBV cure while reducing stigma and discrimination.

Michael Wu, PhD candidate, presented  'A novel LNP/mRNA-based STING immunotherapy approach for chronic HBV infection' poster at the meeting. These findings suggest that uniSTING may be able to overcome immune tolerance in chronic HBV infection and could represent a promising new therapeutic strategy for patients living with the disease.

“The annual HBV 2025 meeting is more than a scientific gathering — it’s a vital exchange of ideas that drives global progress toward eliminating hepatitis B,” said Wu. “Each discovery shared brings us closer to transforming chronic HBV from a lifelong burden into a curable condition. Through ongoing research and collaboration, we’re not just studying the virus — we’re shaping the future of its cure.”

Enlarged poster here: A novel LNP/mRNA-based STING immunotherapy approach for chronic HBV infection

The event also provided opportunities for early and mid-career researchers to strengthen professional communication skills, explore career development, and engage with leading experts in hepatitis B, hepatitis D, and liver cancer research.

This year’s program featured cutting-edge studies on HBV and HDV, the development of new technologies for understanding infection, and discussions on the latest therapeutic advances. The meeting continues to be "the definitive international scientific meeting focused exclusively on the hepatitis B (HBV) and hepatitis D (HDV) viruses”.